



Bernd Seizinger, Professor, MD, PhD

Member of the Board of Directors

Bernd Seizinger is an independent consultant. Until 2009, he was president and chief executive officer of GPC Biotech before its merger with Agennix. Until 1998, he was executive vice president and chief scientific officer of Genome Therapeutics in Waltham/Boston, US. Previously, Mr Seizinger held the posts of vice president of oncology and vice president of corporate and academic alliances at Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, US. Mr Seizinger was formerly associate professor of neuroscience at Harvard Medical School, US; director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital, US; and visiting professor at the department of Molecular Biology at Princeton University, US. He was awarded his MD from the Ludwig Maximilians University and his PhD from the Max Planck Institute of Psychiatry, both in München, Germany. He is the recipient of numerous scientific awards and has authored over 100 publications. Bernd Seizinger is also a member of the board of Agennix (XET: AGX) and chairman of the board of Opsona Therapeutics.